The DOI matches its Crossref record; the references it cites are not checked yet.
Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma
Open accessPublished version of a preprint
Abstract
Purpose: Autophagy consists of lysosome-dependent degradation of cytoplasmic contents sequestered by autophagic vesicles (AV). The role of autophagy in determining tumor aggressiveness and response to therapy in melanoma was investigated in this study. Experimental Design: Autophagy was measured in tumor biopsies obtained from metastatic melanoma patients enrolled on a phase II trial of temozolomide and sorafenib and correlated to clinical outcome. These results were compared with autophagy measurements in aggressive and indolent melanoma cells grown in two- and three-dimensional (3D) culture and as xenograft tumors. The effects of autophagy inhibition with either hydroxychloroquine or inducible shRNA (short hairpin RNA) against the autophagy gene ATG5 were assessed in three-dimensional spheroids. Results: Patients whose tumors had a high autophagic index were less likely to respond to treatment and had a shorter survival compared with those with a low autophagic index. Differences in autophagy were less evident in aggressive and indolent melanoma cells grown in monolayer culture. In contrast, autophagy was increased in aggressive compared with indolent melanoma xenograft tumors. This difference was recapitulated when aggressive and indolent melanoma cells were grown as spheroids. Autophagy inhibition with either hydroxychloroquine or inducible shRNA against ATG5 resulted in cell death in aggressive melanoma spheroids, and significantly augmented temozolomide-induced cell death. Conclusions: Autophagy is a potential prognostic factor and therapeutic target in melanoma. Three dimensional culture mimics the tumor microenvironment better than monolayer culture and is an appropriate model for studying therapeutic combinations involving autophagy modulators. Autophagy inhibition should be tested clinically in patients with melanoma. Clin Cancer Res; 17(10); 3478–89. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent work suggests that malignant melanomas have increased autophagic flux relative to benign nevi78–80.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Induction of autophagy has been suggested to be a pro-survival mechanism for melanoma cells79,81,82.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [79]
In the citing paper
“Autohagy is also associated with proliferation, invasion, and metastasis79, as well as promoting ROS accumulation82.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 40 · Cited by 234
Metadata
- Authors
- Ma, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K.
- Affiliations
- Authors' Affiliations: 1Division of Hematology-Oncology, Department of Medicine; 2Abramson Cancer Center; 3Department of Radiology; 4Division of Medical Genetics, Department of Medicine; 5Institute of Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania; and 6Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, British Columbia, Canada
- BC Cancer Agency (CA)
- Corresponding author
- Amaravadi, Ravi K.
- Venue
- Clinical Cancer Research
- Published
- 2011-05-15
- Volume
- 17
- Issue
- 10
- Pages
- 3478-3489
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3096713
- OpenAlex
- W2139830524
- Cited by
- 234
- References
- 40
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 16 · 2023: 6 · 2022: 17 · 2021: 13 · 2020: 16 · 2019: 13 · 2018: 13 · 2017: 19 · 2016: 25 · 2015: 23 · 2014: 20 · 2013: 20 · 2012: 18
- FWCI
- 15.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abramson Cancer Center
- National Cancer Institute (U54CA105008, K23CA120862, U24CA083105)
- National Center for Research Resources (RR02305, P41RR002305)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Calcium signaling and nucleotide metabolism
- Keywords
- autophagy, melanoma, metastatic melanoma, tumor invasion, chemoresistance, temozolomide, sorafenib, hydroxychloroquine, ATG5, autophagy inhibition, multicellular spheroids, tumor xenografts, prognostic factors, therapeutic target, tumor microenvironment
- MeSH terms
- Sorafenib, Temozolomide, Animals, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Benzenesulfonates, Cell Count, Dacarbazine, Humans, Melanoma, Mice, Nude, Neoplasm Invasiveness, Niacinamide, Phenylurea Compounds, Prognosis, Pyridines, Skin Neoplasms, Tumor Cells, Cultured, Survival Analysis, Clinical Trials, Phase II as Topic, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2372
- The paper
- Ma, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K. (2011). Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.